UK – clock.bio, a Cambridge, UK-based longevity biotech company, launched out of stealth after reaching proof-of-concept with $4M in funding.
Founded by Mark Kotter, clock.bio is developing novel regenerative medicines leveraging the natural ability of human pluripotent stem cells to prevent and treat age-related diseases. The company’s immediate scientific objective is to decode all rejuvenation programs present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation.The company has developed an aging model that force-ages human induced pluripotent stem cells (hiPSCs) and triggers their self-rejuvenation mechanism. Unbiased CRISPR screens on large samples of these cells allow for the identification of gene candidates that are causally relevant for cell rejuvenation. The strategy includes proprietary aging-interventions for iPSCs, unbiased screens for rejuvenation biology, identification and validation of rejuvenation targets and therapeutic lead prioritization and translation into clinical applications.Markus Gstöttner will be joining clock.bio as CEO. Gstöttner co-founded Meatable, a cultured meat company that uses iPSC and opti-ox technologies, which he started with Mark Kotter and others. Building on this cooperation, Gstöttner is currently EIR at BlueYard Capital, with a prior background in public service for the Austrian government, management consulting at McKinsey, and development economics (LSE/J-PAL).31/08/2023
